En fase III-studie av HMPL-760 i kombinasjon med R-GemOx versus placebo i kombinasjon med R-GemOx ved relapserende/refraktær DLBCL
En fase III randomisert, dobbelblind, positivkontrollert studie for å evaluere effekt, sikkerhet og farmakokinetikk av HMPL-760 i kombinasjon med R-GemOx versus placebo i kombinasjon med R-GemOx hos pasienter med tilbakefallende/refraktær diffus storcelle lymfom (DLBCL)
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.
The target population of this study includes patients with DLBCL who are relapsed or refractory.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Dongmei Chen, CPL
- Telefonnummer: 86-21-20671794
- E-post: dongmeic@hutch-med.com
Studiesteder
-
-
-
Baoding, Kina
- Rekruttering
- Baoding NO.1 Central Hospital
-
Ta kontakt med:
- Haiying Yao
- Telefonnummer: 18617789030
- E-post: haiyingyaobd@163.com
-
Hovedetterforsker:
- Haiying Yao
-
Beijing, Kina
- Rekruttering
- Beijing GoBroad Hospital
-
Hovedetterforsker:
- Kai Hu
-
Ta kontakt med:
- Kai Hu
- Telefonnummer: 15010390336
- E-post: HK13610956245@163.com
-
Beijing, Kina
- Rekruttering
- BEIJING TONGREN HOSPITAL, Capital Medical University
-
Hovedetterforsker:
- Liang Wang
-
Ta kontakt med:
- Liang Wang
- Telefonnummer: 15001108693
- E-post: wangliangtrhos@126.com
-
Bengbu, Kina
- Rekruttering
- The First Affiliated Hospital of Bengbu Medical College
-
Ta kontakt med:
- Yanli Yang
- Telefonnummer: 13855249678
- E-post: Yangyanli0702@126.com
-
Hovedetterforsker:
- Yanli Yang
-
Changchun, Kina
- Rekruttering
- The First Hospital of Jilin University
-
Hovedetterforsker:
- Ou Bai
-
Ta kontakt med:
- Ou Bai
- Telefonnummer: 13039046656
- E-post: lbl2054@163.com
-
Changsha, Kina
- Rekruttering
- Hunan Cancer Hospital
-
Hovedetterforsker:
- Hui Zhou
-
Ta kontakt med:
- Hui Zhou
- Telefonnummer: 13975879796
- E-post: zhouhui9403@126.com
-
Changsha, Kina
- Rekruttering
- The Second Xiangya Hospital of Central South University
-
Hovedetterforsker:
- Hongling Peng
-
Ta kontakt med:
- Hongling Peng
- Telefonnummer: 18900766137
- E-post: Penghongling@aliyun.com
-
Changsha, Kina
- Rekruttering
- People's Hospital of Hunan Province
-
Ta kontakt med:
- Can Liu
- Telefonnummer: 137 8728 5260
- E-post: 617170469@qq.com
-
Hovedetterforsker:
- Can Liu
-
Chengdu, Kina
- Rekruttering
- West China Hospital of Sichuan University
-
Hovedetterforsker:
- Liqun Zou
-
Ta kontakt med:
- Liqun Zou
- Telefonnummer: 18980601027
- E-post: Clinical_Zou@163.com
-
Chengdu, Kina
- Rekruttering
- Sichuan Provincial People's Hospital
-
Ta kontakt med:
- Xiaobing Huang
- Telefonnummer: 18981838236
- E-post: hxb_trial@163.com
-
Hovedetterforsker:
- Xiaobing Huang
-
Chongqing, Kina
- Rekruttering
- The First Affiliated Hospital of Chongqing Medical University
-
Hovedetterforsker:
- Xin Wang
-
Ta kontakt med:
- Xin Wang
- E-post: 925170788@qq.com
-
Chongqing, Kina
- Rekruttering
- Chongqing University Cancer Hospital
-
Hovedetterforsker:
- Yao Liu
-
Ta kontakt med:
- Yao Liu
- E-post: liuyao101709@163.com
-
Fujian, Kina
- Rekruttering
- Quanzhou First Hospital.Fujian
-
Ta kontakt med:
- Xiongpeng Zhu
- Telefonnummer: 13805998581
- E-post: xiongpengzhu@163.com
-
Hovedetterforsker:
- Xiongpeng Zhu
-
Fuzhou, Kina
- Rekruttering
- Fujian Medical University Union Hospital
-
Hovedetterforsker:
- Jianzhen Shen
-
Ta kontakt med:
- Jianzhen Shen
- Telefonnummer: 138 0955 2722
- E-post: doctorsjz@163.com
-
Guangzhou, Kina
- Rekruttering
- Sun Yat-sen University Cancer Center
-
Hovedetterforsker:
- Zhiming Li
-
Ta kontakt med:
- Zhiming Li
- Telefonnummer: 13719189172
- E-post: lzmsysu@163.com
-
Guangzhou, Kina
- Rekruttering
- Guangdong Provincial People's Hospital
-
Ta kontakt med:
- Xiaojuan Wei
- Telefonnummer: 86 13560097145
- E-post: jxw919@hotmail.com
-
Hovedetterforsker:
- Xiaojuan Wei
-
Guangzhou, Kina
- Rekruttering
- ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
-
Hovedetterforsker:
- Yuhua Li
-
Ta kontakt med:
- Yuhua Li
- Telefonnummer: 13533706656
- E-post: liyuhua2011gz@163.com
-
Guiyang, Kina
- Rekruttering
- The Affiliated Hospital of Guizhou Medical University
-
Hovedetterforsker:
- Yan Zhang
-
Ta kontakt med:
- Yan Zhang
- Telefonnummer: 86 18984155172
- E-post: Zhangyan20010802@sina.com
-
Hangzhou, Kina
- Rekruttering
- Zhejiang Cancer Hospital
-
Hovedetterforsker:
- Haiyan Yang
-
Ta kontakt med:
- Haiyan Yang
- E-post: 2054451461@qq.com
-
Hangzhou, Kina
- Rekruttering
- The First Affiliated Hospital, Zhejiang University
-
Hovedetterforsker:
- Zhen Cai
-
Ta kontakt med:
- Zhen Cai
- Telefonnummer: 13857190311
- E-post: czclinicaltrial@163.com
-
Harbin, Kina
- Rekruttering
- Harbin Medical University Cancer Hospital
-
Ta kontakt med:
- Qingyuan Zhang
- Telefonnummer: 13313612989
- E-post: sy86298276@163.com
-
Hovedetterforsker:
- Qingyuan Zhang
-
Hefei, Kina
- Rekruttering
- The Second Affiliated Hospital of Anhui Medical University
-
Ta kontakt med:
- Zhimin Zhai
- Telefonnummer: 13855147434
- E-post: zzzm889@163.com
-
Hovedetterforsker:
- Zhimin Zhai
-
Jinan, Kina
- Rekruttering
- Qilu Hospital of Shandong University
-
Ta kontakt med:
- Shuqian Xu
- Telefonnummer: 18560087013
- E-post: yoyoshuqian@126.com
-
Hovedetterforsker:
- Shuqian Xu
-
Jinan, Kina
- Rekruttering
- Shandong Cancer Hospital & Institute
-
Hovedetterforsker:
- Zengjun Li
-
Ta kontakt med:
- Zengjun Li
- Telefonnummer: 15735178591
- E-post: zengjunli@163.com
-
Kunming, Kina
- Har ikke rekruttert ennå
- The First Affiliated Hospital of Kunming Medical University
-
Ta kontakt med:
- Mingxia Shi
- Telefonnummer: 86 138 8806 0581
- E-post: shmxia2002@sina.com
-
Hovedetterforsker:
- Mingxia Shi
-
Nanchang, Kina
- Rekruttering
- Jiangxi Cancer Hospital
-
Hovedetterforsker:
- Yan Huang
-
Ta kontakt med:
- Yan Huang
- E-post: 29265061@qq.com
-
Nanjing, Kina
- Rekruttering
- Jiangsu Cancer Hospital
-
Hovedetterforsker:
- Yan Zhang
-
Ta kontakt med:
- Yan Zhang
- Telefonnummer: 13914712395
- E-post: zhangyan1106@njmu.edu.cn
-
Nanjing, Kina
- Rekruttering
- Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
-
Ta kontakt med:
- Jingyan Xu
- Telefonnummer: 86 13951969610
- E-post: xjy1967@sina.com
-
Hovedetterforsker:
- Jingyan Xu
-
Nanning, Kina
- Rekruttering
- The First Affiliated Hospital of Guangxi Medical University
-
Hovedetterforsker:
- Zhigang Peng
-
Ta kontakt med:
- Zhigang Peng
- E-post: 2557382235@qq.com
-
Qingdao, Kina
- Rekruttering
- The Affiliated Hospital of Qingdao University
-
Ta kontakt med:
- Xia Zhao
- Telefonnummer: 18661803088
- E-post: Zhaoxia@qdu.edu.cn
-
Hovedetterforsker:
- Xia Zhao
-
Shanghai, Kina
- Rekruttering
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
Hovedetterforsker:
- Weili Zhao
-
Ta kontakt med:
- Weili Zhao
- Telefonnummer: 86 13512112076
- E-post: zwl_trial@163.com
-
Shanghai, Kina
- Rekruttering
- Tongji Hospital of Tongji University
-
Ta kontakt med:
- Ping Li
- Telefonnummer: 13564181131
- E-post: lilyforever76@126.com
-
Hovedetterforsker:
- Ping Li
-
Shanghai, Kina
- Har ikke rekruttert ennå
- Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
-
Hovedetterforsker:
- Ligen Liu
-
Ta kontakt med:
- Ligen Liu
- Telefonnummer: 86 18017337037
- E-post: llg3532@shtrhospital.com
-
Shenyang, Kina
- Rekruttering
- Shengjing Hospital of China Medical University
-
Hovedetterforsker:
- Wei Yang
-
Ta kontakt med:
- Wei Yang
- Telefonnummer: 18940251012
- E-post: sjyangw@163.com
-
Shenzhen, Kina
- Rekruttering
- Shenzhen people's hospital
-
Hovedetterforsker:
- Jihao Zhou
-
Ta kontakt med:
- Jihao Zhou
- Telefonnummer: 86 18718678693
- E-post: zhoujihao@aliyun.com
-
Taiyuan, Kina
- Rekruttering
- Shanxi Provincial Cancer Hospital
-
Hovedetterforsker:
- Liping Su
-
Ta kontakt med:
- Liping Su
- Telefonnummer: 13835158122
- E-post: slpsy2022@163.com
-
Tangshan, Kina
- Rekruttering
- North China University of Science and Technology Affiliated Hospital
-
Ta kontakt med:
- Zhenyu Yan
- Telefonnummer: 15931508262
- E-post: hbyzy2011@163.com
-
Hovedetterforsker:
- Zhenyu Yan
-
Tianjin, Kina
- Rekruttering
- Tianjin Medical University Cancer Institute & Hospital
-
Hovedetterforsker:
- Zhengzi Qian
-
Ta kontakt med:
- Zhengzi Qian
- Telefonnummer: 13702031222
- E-post: qzz@163.com
-
Tianjin, Kina
- Rekruttering
- Tianjin People's Hospital
-
Ta kontakt med:
- Xingli Zhao
- Telefonnummer: 13752255454
- E-post: insectzhao@163.com
-
Hovedetterforsker:
- Xingli Zhao
-
Tianjin, Kina
- Rekruttering
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
Hovedetterforsker:
- Dehui Zou
-
Ta kontakt med:
- Dehui Zou
- Telefonnummer: 13602100955
- E-post: zoudehui@ihcams.ac.cn
-
Wenzhou, Kina
- Rekruttering
- The First Affiliated Hospital of WMU
-
Ta kontakt med:
- Songfu Jiang
- Telefonnummer: 86 15305770033
- E-post: jiangsongfu@189.cn
-
Hovedetterforsker:
- Songfu Jiang
-
Wuhan, Kina
- Rekruttering
- Hubei Cancer Hospital
-
Hovedetterforsker:
- Huijing Wu
-
Ta kontakt med:
- Huijing Wu
- E-post: 3269614878@qq.com
-
Wuhan, Kina
- Rekruttering
- Wuhan Union Hospital of China
-
Hovedetterforsker:
- Liling Zhang
-
Ta kontakt med:
- Liling Zhang
- Telefonnummer: 15871725926
- E-post: lily1228@sina.com
-
Xi'an, Kina
- Rekruttering
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Hovedetterforsker:
- Pengcheng He
-
Ta kontakt med:
- Pengcheng He
- Telefonnummer: 18991232609
- E-post: hepc_gcp@163.com
-
Xi'an, Kina
- Rekruttering
- The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
-
Hovedetterforsker:
- Jie Liu
-
Ta kontakt med:
- Jie Liu
- Telefonnummer: 86 18092662371
- E-post: lieujie@163.com
-
Xiamen, Kina
- Har ikke rekruttert ennå
- The First Affiliated Hospital of Xiamen University
-
Hovedetterforsker:
- Bing Xu
-
Ta kontakt med:
- Bing Xu
- Telefonnummer: 86 18750918842
- E-post: xubingzhangjian@126.com
-
Xuzhou, Kina
- Rekruttering
- The Affiliated Hospital of Xuzhou Medical University
-
Ta kontakt med:
- Wei Sang
- Telefonnummer: 86 13645207648
- E-post: 13645207648@126.com
-
Hovedetterforsker:
- Wei Sang
-
Zhengzhou, Kina
- Rekruttering
- Henan Cancer Hospital
-
Hovedetterforsker:
- Keshu Zhou
-
Ta kontakt med:
- Keshu Zhou
- Telefonnummer: 13674902391
- E-post: dr_zkshu23810@163.com
-
Zhengzhou, Kina
- Rekruttering
- The First Affiliated Hospital of Zhengzhou University
-
Ta kontakt med:
- Xudong Zhang
- Telefonnummer: 13633825183
- E-post: feverxxd@126.com
-
Hovedetterforsker:
- Xudong Zhang
-
Ürümqi, Kina
- Rekruttering
- People's Hospital of Xinjiang Uygur Autonomous Region
-
Hovedetterforsker:
- Yan Li
-
Ta kontakt med:
- Yan Li
- Telefonnummer: 86 13639935315
- E-post: liyan232917@139.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina
- Rekruttering
- Fudan University Shanghai Cancer Center
-
Ta kontakt med:
- Fangfang Lv
- Telefonnummer: 18017312613
- E-post: Lvff80@163.com
-
Hovedetterforsker:
- Fangfang Lv
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Sign the ICF and be able to follow the requirements of study protocol;
- Age ≥18 years;
- ECOG performance status score between 0 and 2;
- Histopathologically confirmed diagnosis of DLBCL;
- The investigator judges that the patient's current condition requires further treatment;
- Patients should have at least one bi-dimensionally measurable lesion;
- Expected survival is more than 12 weeks;
Exclusion Criteria:
- Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
- Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
- Organ insufficiency;
- Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
- History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
- Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
- The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
- Clinically significant active infection;
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: The experimental group
Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle. |
Patients will receive HMPL-760 once daily (QD) orally. R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Andre navn:
|
|
Placebo komparator: The control group
Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group. |
R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Andre navn:
Patients will receive HMPL-760 placebo once daily (QD) orally. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival (PFS)
Tidsramme: Up to approximately two years
|
Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first. |
Up to approximately two years
|
|
End of treatment (EOT)
Tidsramme: Up to approximately two years
|
Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy). |
Up to approximately two years
|
|
Systemic antitumor therapy
Tidsramme: Up to approximately two years
|
Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy). |
Up to approximately two years
|
|
Overall survival (OS)
Tidsramme: Up to approximately two years
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately two years
|
|
systematic anti-tumor therapy
Tidsramme: Up to approximately two years
|
OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
|
Premature withdrawal from study treatment
Tidsramme: Up to approximately two years
|
OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Independent review committee (IRC)-assessed PFS
Tidsramme: Up to approximately two years
|
Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). |
Up to approximately two years
|
|
IRC- and investigator-assessed objective response rate (ORR)
Tidsramme: Up to approximately two years
|
Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) |
Up to approximately two years
|
|
IRC- and investigator-assessed complete response rate (CRR)
Tidsramme: Up to approximately two years
|
Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR) |
Up to approximately two years
|
|
IRC- and investigator-assessed duration of response (DoR)
Tidsramme: Up to approximately two years
|
For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first |
Up to approximately two years
|
|
IRC- and investigator-assessed clinical benefit rate (CBR)
Tidsramme: Up to approximately two years
|
Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD) |
Up to approximately two years
|
|
IRC- and investigator-assessed time to response (TTR)
Tidsramme: Up to approximately two years
|
Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR) |
Up to approximately two years
|
|
Safety Endpoints
Tidsramme: Up to approximately two years
|
|
Up to approximately two years
|
|
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Tidsramme: At the end of Cycle 4 (each cycle is 21 days)]
|
including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. |
At the end of Cycle 4 (each cycle is 21 days)]
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Biomarker assessment
Tidsramme: Up to approximately two years
|
Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy. |
Up to approximately two years
|
|
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Tidsramme: Up to approximately two years
|
Human metabolites of HMPL-760 when co-administered with R-GemOx |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years
|
maximum concentration in steady-state (Cmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years
|
time to maximum concentration in steady-state (Tmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years
|
Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years
|
The rate at which the drug is eliminated from the body (CL/F) (if applicable ) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Tidsramme: Up to approximately two years
|
The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable) |
Up to approximately two years
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Weili Zhao, Ruijin Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom, B-celle
- Lymfom
- Hemic og lymfatiske sykdommer
- Lymfom, stor B-celle, diffus
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Terapeutikk
- Drug Administration -ruter
- Medikamentell terapi
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Koordinasjonskomplekser
- Deoxycytidine
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Antistoffer, monoklonale, murine-avledede
- Oksaliplatin
- Rituximab
- Gemcitabin
- Injeksjoner
Andre studie-ID-numre
Andre studie-ID-numre
- 2025-760-00CH1
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .